AMERICAN SHARED HOSPITAL SERVICES - Quarter Report: 2007 September (Form 10-Q)

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2007 or

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     .

American Shared Hospital Services

California (State or other jurisdiction of Incorporation or organization)		94-2918118 (IRS Employer Identification No.)
Four Embarcadero Center, Suite 3700, San Francisco, California (Address of Principal Executive Offices)		94111 (Zip Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ      No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer o                 Accelerated Filer o                 Non-Accelerated Filer þ

Indicated by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o     No þ

As of November 1, 2007, there are outstanding 5,026,587 shares of the Registrant’s common stock.

 

 

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AMERICAN SHARED HOSPITAL SERVICES
CONDENSED CONSOLIDATED BALANCE SHEETS

		(unaudited)				(audited)
		September 30, 2007				December 31, 2006
ASSETS
Current assets:
Cash and cash equivalents		$	4,346,000			$	3,952,000
Restricted cash			50,000				50,000
Securities			2,855,000				1,574,000
Accounts receivable, net of allowance for doubtful accounts of $170,000 in 2007 and $170,000 in 2006			4,721,000				4,248,000
Other receivables			202,000				102,000
Prepaid expenses and other assets			390,000				598,000
Current deffered tax assets			601,000				601,000
Total current assets			13,165,000				11,125,000
Property and equipment:
Medical equipment and facilities			63,748,000				61,828,000
Office equipment			691,000				515,000
Deposits and construction in progress			13,796,000				3,137,000
			78,235,000				65,480,000
Accumulated depreciation and amortization			(35,790,000	)			(31,314,000	)
Net property & equipment			42,445,000				34,166,000
Securities-long term			2,140,000				3,380,000
Investment in preferred stock			2,617,000				2,000,000
Other assets			293,000				234,000
Total assets		$	60,660,000			$	50,905,000
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	330,000			$	340,000
Other interest and other liabilities			866,000				913,000
Customer deposits			2,980,000				100,000
Employee compensation and benefits			204,000				116,000
Accrued dividends			0				239,000
Income taxes payable			320,000				82,000
Advances on line of credit			4,200,000				4,000,000
Current portion of long-term debt			6,358,000				4,867,000
Current portion of long-term capital leases			1,097,000				1,009,000
Total current liabilities			16,355,000				11,666,000
Long-term debt, less current portion			16,835,000				11,378,000
Long-term capital leases, less current portion			3,000,000				3,811,000
Deferred income taxes			1,996,000				1,996,000
Minority interest			3,117,000				3,045,000
Shareholders’ equity:
Common stock, without par value: authorized shares - 10,000,000; issued & outstanding shares, 5,026,587 in 2007 and 5,023,418 in 2006			9,320,000				9,317,000
Additional paid-in capital			4,298,000				4,251,000
Retained earnings			5,739,000				5,441,000
Total shareholders’ equity			19,357,000				19,009,000
Total liabilities and shareholders’ equity		$	60,660,000			$	50,905,000

See accompanying notes

AMERICAN SHARED HOSPITAL SERVICES
CONDENSED CONSOLIDATED INCOME STATEMENT
(Unaudited)

		Three months ended Sep. 30,								Nine months ended Sep. 30,
		2007				2006				2007				2006
Revenue:
Medical services revenue		$	4,652,000			$	5,238,000			$	14,311,000			$	15,592,000
Costs and expenses:
Costs of revenue:
Maintenance and supplies			380,000				320,000				959,000				964,000
Depreciation and amortization			1,514,000				1,466,000				4,406,000				4,382,000
Other direct operating costs			602,000				803,000				2,114,000				2,540,000
			2,496,000				2,589,000				7,479,000				7,886,000
Gross margin			2,156,000				2,649,000				6,832,000				7,706,000
Selling and administrative expense			1,038,000				1,109,000				3,408,000				3,101,000
Interest expense			434,000				540,000				1,371,000				1,663,000
Operating income			684,000				1,000,000				2,053,000				2,942,000
Interest and other income			96,000				68,000				314,000				245,000
Minority interest expense			(273,000	)			(360,000	)			(908,000	)			(1,025,000	)
Income before income taxes			507,000				708,000				1,459,000				2,162,000
Income tax expense			239,000				283,000				686,000				853,000
Net income		$	268,000			$	425,000			$	773,000			$	1,309,000
Earnings per share:
Basic		$	0.05			$	0.08			$	0.15			$	0.26
Diluted		$	0.05			$	0.08			$	0.15			$	0.26
Basic shares			5,026,000				5,023,000				5,024,000				5,022,000
Diluted shares			5,041,000				5,047,000				5,047,000				5,051,000

See accompanying notes

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED CASH FLOWS STATEMENT

(Unaudited)

		Nine months ended Sep. 30,
		2007				2006
Operating activities:
Net income		$	773,000			$	1,309,000
Adjustments to reconcile net cash provided by operating activities:
Depreciation and amortization			4,494,000				4,458,000
Deferred income taxes			238,000				853,000
Loss on sale of assets			0				3,000
Stock based compensation expense			51,000				25,000
Minority interest in consolidated subsidiaries			908,000				1,025,000
Changes in operating assets and liabilities:
Receivables			(573,000	)			(683,000	)
Prepaid expenses and other assets			131,000				(13,000	)
Customer deposits			2,880,000				100,000
Accounts payable and accrued liabilities			31,000				(225,000	)
Net cash from operating activities			8,933,000				6,852,000
Investing activities:
Payment for purchase of property and equipment			(12,755,000	)			(1,530,000	)
Proceeds from sale and maturity of marketable securities			1,698,000				3,983,000
Investment in marketable securities			(1,739,000	)			(3,039,000	)
Investment in convertible preferred stock			(617,000	)			(2,000,000	)
Proceeds from sale of assets			0				20,000
Net cash from investing activities			(13,413,000	)			(2,566,000	)
Financing activities:
Principal payments on long-term debt			(4,028,000	)			(4,302,000	)
Principal payments on capital leases			(723,000	)			(678,000	)
Long-term debt financing on purchase of property and equipment			10,976,000				0
Advances on line of credit			2,425,000				4,550,000
Payments on line of credit			(2,225,000	)			(1,100,000	)
Payment of dividends			(715,000	)			(715,000	)
Distribution to minority owners			(836,000	)			(703,000	)
Proceeds from exercise of stock options			0				5,000
Net cash from financing activities			4,874,000				(2,943,000	)
Net change in cash and cash equivalents			394,000				1,343,000
Cash and cash equivalents at beginning of period			3,952,000				1,298,000
Cash and cash equivalents at end of period		$	4,346,000			$	2,641,000
Supplemental cash flow disclosure:
Cash paid during the period for:
Interest		$	1,642,000			$	1,663,000
Income taxes		$	448,000			$	309,000
Schedule of noncash investing and financial activities:
Accrued dividends		$	0			$	239,000
Acquisition of equipment with capital lease financing		$	0			$	1,540,000

See accompanying notes

AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 1. Basis of Presentation

     In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly American Shared Hospital Services’ consolidated financial position as of September 30, 2007 and the results of its operations for the three and nine month periods ended September 30, 2007 and 2006, which results are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2006 have been derived from audited financial statements.

     These unaudited consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2006 included in the Company’s 10-K and 10-K/A filed with the Securities and Exchange Commission.

     These financial statements include the accounts of American Shared Hospital Services (the “Company”) and its wholly-owned subsidiaries: OR21, Inc. (“OR21”); MedLeader.com, Inc. (“MedLeader”); American Shared Radiosurgery Services (“ASRS”); and ASRS majority-owned subsidiary, GK Financing, LLC (“GK Financing”).

     The Company through its majority-owned subsidiary, GK Financing, provided Gamma Knife units to twenty medical centers as of September 30, 2007 in Arkansas, California, Connecticut, Florida, Illinois, Maryland, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Pennsylvania, Texas and Wisconsin.

     In 2006 the Company contracted to provide certain additional radiation therapy and related equipment which includes Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site. This equipment became operational during September 2007.

     All significant intercompany accounts and transactions have been eliminated in consolidation.

     Certain reclassifications have been made to the 2006 balances to conform with the 2007 presentation.

Note 2. Per Share Amounts

     Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. For both the three and nine months ended September 30, 2007 basic earnings per share was computed using 5,024,000 common shares, and diluted earnings per share was computed using 5,041,000 and 5,047,000 common shares and equivalents, respectively. For the three and nine months ended September 30, 2006 basic earnings per share was computed using 5,023,000 and 5,022,000 common shares, respectively, and diluted earnings per share was computed using 5,047,000 and 5,051,000 common shares and equivalents, respectively.

Note 3. Stock-based Compensation

     On September 28, 2006, the Company’s shareholders approved the 2006 Stock Incentive Plan (the “2006 Plan”) under which 750,000 shares of the Company’s common stock are reserved for issuance of shares to officers of the Company, other key employees, non-employee directors, and advisors. The 2006 Plan serves as successor to the Company’s previous two stock-based employee compensation plans, the 1995 and 2001 Stock Option Plans. The shares reserved under those two plans, including the shares of common stock subject to currently outstanding options under the plans, were transferred to the 2006 Plan, and no further grants or share issuances will be made under the 1995 Plan or 2001 Plans. Under the 2006 Plan, there are 1,500 restricted stock units granted, consisting of annual automatic grants to non-employee directors, and approximately 198,000 options granted, of which approximately 107,000 options are vested, as of September 30, 2007.

     Through 2005, the Company accounted for these plans using the intrinsic value method prescribed by APB Opinion No. 25, Accounting for Stock Issued to employees, and related Interpretations. No stock-based employee compensation cost was reflected in net income as all options granted under those plans had an exercise price greater than or equal to the market value of the underlying common stock on the date of grant.

     Beginning in 2006, in accordance with FASB Statement No. 123R, Accounting for Stock-Based Compensation, the Company began expensing the fair value of its stock options issued, using the modified prospective format. The Company’s stock-based awards to employees are calculated using the Black-Scholes valuation model. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the present value estimates. The estimated fair value of the Company’s option grants awarded during 2007 was estimated assuming the following weighted-average assumptions: ten year expected life, 68% expected volatility, 2.9% dividend yield, and 4.9% risk-free interest rate. The estimated fair value of the Company’s options is amortized over the period during which an employee is required to provide service in exchange for the award, usually the vesting period. Accordingly, stock-based compensation cost before income tax effect in the amount of approximately $18,000 is reflected in third quarter 2007 net income, and $51,000 is reflected in year to date net income, compared to approximately $9,000 and $25,000 in the same periods in the prior year, respectively.

     FASB Statement No. 123R requires that excess tax benefits be reported as a financing cash inflow rather than as a reduction of taxes paid. There were 56,000 options issued and 2,000 options exercised during the nine month period ended September 30, 2007. There were no excess tax benefits to report.

Note 4. Convertible Preferred Stock Investment

     On April 10, 2006 the Company invested $2,000,000 for a convertible preferred stock interest in Still River Systems, Inc. (“Still River”), a development-stage company based in Littleton, Massachusetts, which in collaboration with scientists from MIT’s Plasma Science and Fusion Center, is developing a medical device for the treatment of cancer patients using proton beam radiation therapy (PBRT). The Company also purchased for $1,000,000 an option to acquire two Monarch 250™ (formerly Clinatron 250™) PBRT systems from Still River for anticipated delivery in 2009. The PBRT systems are not currently FDA approved.

     The Company’s initial investment in Still River consisted of approximately 2,353,000 shares of Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock is considered pari passu with previously issued Series A Convertible Preferred Stock.

     On September 5, 2007 the Company invested approximately $617,000 for an additional equity interest in Still River Systems, Inc. This investment represents approximately 588,000 shares of Series C Convertible Preferred Stock, which is considered pari passu with the previously issued Series A and Series B Convertible Preferred Stock (all issues together “Preferred Stock”). Upon conversion, the investment increases the Company’s common stock interest in Still River to approximately 7.6%.

     The Preferred Stock is convertible at any time at the option of the holder into shares of common stock of Still River at a conversion price, subject to certain adjustments, but initially set at the original purchase price. The Preferred Stock has voting rights equivalent to the number of common stock shares into which it is convertible, and holders of the Preferred Stock, subject to certain exceptions, have a pro-rata right to participate in subsequent stock offerings. In the event of liquidation, dissolution, or winding up of Still River, the Preferred Stock holders have preference to the holders of common stock, and any other class or series of stock that is junior to the Preferred Stock. The Company does not have a Board of Directors seat with Still River.

     The Company accounts for its investment in Still River under the cost method.

Note 5. Line of Credit

     The Company has a $6,000,000 line of credit with the Bank of America (the “Bank”), which is renewable annually and is drawn on from time to time as needed for equipment purchases and working capital. Amounts drawn against the line of credit are at an interest rate per year equal to the Bank’s Prime Rate minus 1.5 percentage points, or alternately the LIBOR rate plus 0.95 percentage points, and are secured by the Company’s cash invested with the Bank. At September 30, 2007, $4,200,000 was borrowed against the line of credit.

Note 6. Equipment Deposits

     The Company has recorded under Current liabilities approximately $3,000,000 in deposits received from customers towards the eventual purchase of equipment at the end of their lease terms. Payments made by the Company to suppliers for related equipment is recorded in Property and equipment.

Note 7. Accounting for Uncertainty in Income Taxes

     Effective January 1, 2007, the Company adopted Financial Accounting Standards Interpretation, or FIN, No. 48, “Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109” (FIN 48).  FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

     The cumulative effect of adopting FIN 48 is recognized as a change in accounting principle, and any adjustment required as the result of adoption would be recorded as an adjustment to the opening balance of retained earnings on January 1, 2007. As a result of the implementation of FIN 48, the Company recognized no change in the liability for unrecognized tax benefits related to tax positions taken in prior periods, and no corresponding change in retained earnings.

     Additionally, FIN 48 specifies that tax positions for which the timing of the ultimate resolution is uncertain should be recognized as long-term liabilities. The Company made no reclassifications between current taxes payable and long term taxes payable upon adoption of FIN 48. Also, the Company had no amounts of unrecognized tax benefits that, if recognized, would affect its effective income tax rate for January 1, 2007 and September 30, 2007.

     The Company’s policy for deducting interest and penalties is to treat interest as interest expense and penalties as taxes. As of September 30, 2007 the Company had no amount accrued for the payment of interest and penalties related to unrecognized tax benefits and no amounts as of the adoption date of FIN 48.

     The tax return years 2002 through 2006 remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company in 1995 through 1997 and 1999 through 2004 remain open to examination by the major domestic taxing jurisdictions.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     This quarterly report to the Securities and Exchange Commission may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services, which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife and IMRT business, the risk of developing the Company’s PBRT business and The Operating Room for the 21^st Century® program, and the risks of investing in a development-stage company, Still River Systems, Inc., without a proven product. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital

Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K and 10-K/A for the year ended December 31, 2006, the Form 10-Q for the three months ended March 31, 2007 and three months ended June 30, 2007, and the definitive Proxy Statement for the Annual Meeting of Shareholders on June 14, 2007.

     Medical services revenue decreased $586,000 and $1,281,000 to $4,652,000 and $14,311,000 for the three and nine month periods ended September 30, 2007 from $5,238,000 and $15,592,000 for the three and nine month periods ended September 30, 2006, respectively. The decrease for the three and nine month period is partially due to downtime of approximately six weeks at one Gamma Knife site that was being upgraded to the new Gamma Knife Perfexion system. For the three month period, the reduction is also due to generally lower volumes at some of the other Gamma Knife sites, which resulted in a reduction to 575 from 664 in the number of Gamma Knife procedures performed. The decrease for the nine month period was also caused by cobalt reloads at two of the Company’s existing sites, one in first quarter and one in second quarter, which caused each unit to be out of service for several weeks, and generally lower volume of Gamma Knife procedures performed. The Company’s new contract to provide additional radiation therapy and related equipment and services at an existing Gamma Knife customer site began operation during September 2007 and contributed approximately $85,000 of revenue, which partially offset the decrease in Gamma Knife revenue.

     The Company had twenty Gamma Knife units in operation at September 30, 2007 compared to twenty-one Gamma Knife units at September 30, 2006. One Gamma Knife contract terminated in September 2007 at the end of its term. Another contract is scheduled to terminate in early 2008 at the end of its term. Currently fifteen of the Company’s Gamma Knife customers are under fee-per-use contracts, and five customers are under retail arrangements. Retail arrangements are further classified as either turn-key or net revenue sharing. Revenue from fee per use contracts is recorded on a gross basis as determined by each hospital’s contracted rate. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and is responsible for paying all the operating costs of the Gamma Knife. Revenue is recorded on a gross basis and estimated based on historical experience and hospital contracts with third party payors. For net revenue sharing arrangements the Company receives a contracted percentage of the reimbursement received by the hospital less the operating expenses of the Gamma Knife. Revenue is recorded on a net basis and estimated based on historical experience.

     The equipment provided under the Company’s contract to provide additional radiation therapy and related equipment services to an existing Gamma Knife customer began operation in September 2007. This contract is considered a retail arrangement and revenue is recorded on a revenue sharing basis.

     The number of Gamma Knife procedures decreased by 13% to 575 and by 8% to 1,803 for the three and nine month periods ended September 30, 2007 from 664 and 1,967 for the three and nine month periods ended September 30, 2006, respectively. The decrease for the three and nine month period was due to generally lower volume at several Gamma Knife sites and downtime of approximately six weeks at one Gamma Knife site that is being upgraded to the Perfexion model. The decrease for the nine month period is also due to cobalt reloads at two of the Company’s existing sites.

     Total costs of revenue decreased $93,000 and $407,000 to $2,496,000 and $7,479,000 for the three and nine month periods ended September 30, 2007 from $2,589,000 and $7,886,000 for the three and nine months periods ended September 30, 2006. Maintenance and supplies increased by $60,000 and decreased by $5,000 for the three and nine month periods ended September 30, 2007 compared to the same periods in the prior year. For the quarter, this is primarily due to increased cost for maintenance contracts upon renewal and the start of contract maintenance for one Gamma Knife unit upon the completion of the warranty period. For the nine month period the variance is due to higher contract maintenance costs offset by lower costs for repairs not covered under maintenance contract. Depreciation and amortization increased by $48,000 and $24,000 for the three and nine month periods ended September 30, 2007 compared to the same periods in the prior year, primarily because of higher depreciation expense at two Gamma Knife sites where cobalt was reloaded in first and second quarter 2007. Other direct operating costs decreased $201,000 and $426,000 for the three and nine month periods ended September 30, 2007 compared to the same periods in the prior year. For both the three month and nine month periods, the decrease is primarily due to lower marketing costs and property taxes. For the nine month period the decrease is also due to lower operating costs at retail turn-key sites where the Company is responsible for paying all the direct operating costs.

     Selling and administrative costs decreased by $71,000 and increased by $307,000 to $1,038,000 and $3,408,000 for the three and nine month periods ending September 30, 2007 compared to $1,109,000 and $3,101,000 for the same periods in the prior year. For the three month period, the decrease was primarily due to lower business development costs, legal fees and contributions, partially offset by higher building rent and accounting fees. For the nine month period the increase is primarily due to higher consulting fees and accounting fees related to the implementation of new accounting standards, partially offset by lower legal fees and contributions.

     Interest expense decreased by $106,000 and $292,000 to $434,000 and $1,371,000 for the three and nine month periods ended September 30, 2007 from $540,000 and $1,663,000 for the three and nine month periods ended September 30, 2006 primarily due to the completion of debt service for three term loans during 2006 and one during 2007 and lower interest expense on the debt relating to the more mature Gamma Knife units. The mature units have lower interest expense because interest expense decreases as the outstanding principal balance of each loan is reduced. The reduction in interest expense on these term loans was partially offset by increased interest expense from borrowing under the Company’s line of credit with a bank.

     Interest and other income increased by $28,000 and $69,000 to $96,000 and $314,000 for the three and nine month periods ended September 30, 2007 from $68,000 and $245,000 for the three and nine month periods ended September 30, 2006 primarily due to increased interest income as a result of higher available interest rates and higher invested cash balances.

     Minority interest expense decreased by $87,000 and $117,000 to $273,000 and $908,000 for the three and nine month periods ended September 30, 2007 from $360,000 and $1,025,000 for the three and nine month periods ended September 30, 2006 due to reduced profitability of GK Financing. Minority interest represents the 19% interest of GK Financing owned by a third party.

     Income tax expense decreased by $44,000 and $167,000 to $239,000 and $686,000 for the three and nine month periods ended September 30, 2007 compared to $283,000 and $853,000 for the three and nine month periods ended September 30, 2006. For the three and nine month periods ended September 30, 2007, the Company recorded a 47% income tax provision, compared to a 40% and 39% income tax provision for the three and nine month periods ended September 30, 2006, respectively, primarily due to increased income at the subsidiary level in certain states where there are separate state income tax filing requirements. However, income tax expense is lower because income before income taxes is $201,000 and $703,000 lower for the three and nine month periods ending September 30, 2007 compared to the same periods in the prior year, respectively.

     The Company had net income of $268,000 ($0.05 per diluted share) and $773,000 ($0.15 per diluted share) for the three and nine month periods ended September 30, 2007 compared to net income of $425,000 ($0.08 per diluted share) and $1,309,000 ($0.26 per diluted share) for the same periods in the prior year. The decrease for both the three and nine month periods is primarily due to lower revenue from the Gamma Knife units, and for the nine month period is also due to increased selling and administrative costs.

Liquidity and Capital Resources

     The Company had cash and cash equivalents of $4,346,000 at September 30, 2007 compared to $3,952,000 at December 31, 2006. The Company’s cash position increased by $394,000 primarily due to an increase in net cash from operating activities of $8,933,000 which included an increase in customer deposits of $2,880,000 representing advance payments from an existing customer towards the eventual purchase of the Gamma Knife unit at that site upon the expiration of their contract. It is also due to proceeds from sale and maturity of marketable securities of $1,698,000, borrowing under the Company’s line of credit with a bank in the amount of $2,425,000 and debt financing towards the purchase of property and equipment of $10,976,000. These increases were partially offset by payments for the purchase of property and equipment of $12,755,000, investment in marketable securities of $1,739,000, principal payments on long term debt and capital leases of $4,751,000, payments towards the Company’s line of credit of $2,225,000, distributions to minority owners of $836,000, investment in convertible preferred stock of $617,000 and payment of shareholder dividends of $715,000.

     During the nine month period ended September 30, 2007, the Company paid quarterly dividends of $239,000, or $0.0475 per share, in first, second and third quarters. On September 21, 2007 the Company announced that it had suspended future dividends in order to preserve cash for its new business opportunities.

     The Company as of September 30, 2007 had shareholders’ equity of $19,357,000, negative working capital of $3,190,000 and total assets of approximately $60,660,000. The negative working capital is primarily due to the classification of customer deposits towards the purchase of equipment at the end of the lease term of approximately $3,000,000 in current liabilities, and the related equipment in Property and equipment, which is not a current asset.

     The Company has scheduled interest and principal payments under its debt obligations of approximately $7,501,000 and scheduled capital lease payments of approximately $1,191,000 during the next 12 months. The Company believes that its cash flow from operations and cash resources are adequate to meet its scheduled debt and capital lease obligations during the next 12 months.

     The Company has a $6,000,000 line of credit, renewable annually, available as needed for equipment purchases and working capital. Amounts drawn against the line of credit are secured by the Company’s cash invested with the bank. At September 30, 2007 there was $4,200,000 drawn against the line of credit.

     The Company invests its cash primarily in money market or similar funds and high quality short to long-term fixed income securities in order to maximize current income while minimizing the potential for principal erosion. A portion of these investments are classified as securities on the balance sheet and are considered held-to-maturity investments because it is the company’s ability and intent to hold these securities until maturity. Securities with maturity dates between three and twelve months in the amount of $2,855,000 are classified as current assets. Securities in the amount of $2,140,000 have maturities in excess of one year and are classified as long-term.

     In September 2007 The Company invested an additional $617,000 in preferred stock of Still River Systems, Inc. The total convertible preferred stock investment of $2,617,000 in Still River is considered a long-term investment on the balance sheet and is recorded at cost. The Company has also made deposits of $1,000,000 per machine towards the purchase of two Still River Monarch 250 systems, which are classified under Deposits and construction in progress. The Company used its line of credit to fund the investment and initial deposit. During first quarter 2007 interim financing was obtained from a lender for the total amount of the deposits paid to date. The Company has a commitment to pay additional deposits of $2,000,000 per machine until FDA approval is received, at which time the remaining balance towards the purchase of the equipment is committed. It is anticipated that similar interim financing will be available on the future deposits.

     The Company also made deposits totaling $930,000 in fourth quarter 2006 and $310,000 in first quarter 2007 towards the purchase of four Gamma Knife Perfexion™ units. Financing has been obtained on two of the units where the Company has obtained placement commitments from customers. An existing customer has entered into an agreement to replace its existing Gamma Knife with the third Perfexion unit and purchasing it in conjunction with the expiration of its lease agreement with the Company in early 2008. A lender has provided a commitment to provide funding on the fourth unit, once a customer contract to place the unit has been obtained.

     At the end of the customer contract in third quarter 2007, the Company removed and traded in the existing Gamma Knife at that site towards the future purchase of a LGK Model 4 Gamma Knife at a site still to be determined.

     Including the commitments for the two Monarch 250 systems, the 4 Perfexion™ units and the LGK Model 4 Gamma Knife, the Company has total remaining commitments to purchase equipment in the amount of approximately $28,000,000. The Company believes it has the ability, and it is its intent, to finance these purchase commitments as needed.

Item 4. Controls and Procedures

     (a) Evaluation of disclosure controls and procedures. Our Chief Executive Officer and our Chief Financial Officer, after evaluating the effectiveness of the Company’s “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (“Exchange Act”) Exchange Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this quarterly report, have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.

     (b) Changes in internal control over financial reporting. Our Chief Executive Officer and our Chief Financial Officer have evaluated the changes to the Company’s internal control over financial reporting that occurred during our last fiscal quarter ended September 30, 2007, as required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15, and have concluded that there were no such changes that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

     None.

Item 1A. Risk Factors

     There are no changes from those listed in the Company’s Annual Report on Form 10-KA for the year ended December 31, 2006.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

     None.

Item 3. Defaults Upon Senior Securities.

     None.

Item 4. Submission of Matters to a Vote of Securities Holders.

     None.

Item 5. Other Information.

     None.

Item 6. Exhibits

(a) Exhibits

     The following exhibits are filed herewith:

Exhibit Number		Description
10.19b		Ammendment to Lease Agreement for Gamma Knife Unit effective June 30, 2006 between GK Financing, LLC and Yale-New Haven Ambulatory Services Corporation and Yale-New Haven Hospital, Inc. a/k/a Yale-New Haven Hospital. (Confidential material appearing in this document has been omitted and filed separately with the Securities and Exchange Commission in accordance with Rule 24b-2, promulgated under the Securities and Exchange Act of 1934, as amended. Omitted information has been replaced with asterisks).
31.1		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMERICAN SHARED HOSPITAL SERVICES
Registrant